Form D · Biotechnology
Foldax, Inc.
Salt Lake City, UT · CIK 0001602708
Offering snapshot reported Nov 7, 2023 · SEC filing
- Reported sold
- $7M Indefinite offering
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 7, 2023 | Initial | $7,000,000 | No comparison | 10 | SEC filing |
| Jan 13, 2022 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 19, 2018 | Initial | $10,300,118 | No comparison | 15 | SEC filing |
| May 12, 2017 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Jul 26, 2016 | Initial | $3,075,000 | No comparison | 9 | SEC filing |
| Sep 8, 2015 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| Jun 16, 2015 | Initial | $350,000 | No comparison | 2 | SEC filing |
| Aug 21, 2014 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Aug 21, 2014 | Amendment | $50,000 | $0vs Aug 21, 2014 | 1 | SEC filing |
| Apr 21, 2014 | Initial | $150,000 | No comparison | 3 | SEC filing |
| Mar 18, 2014 | Initial | $15,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-496630
Source: Form D, filed Nov 7, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Greg Casciaro | Director, Executive |
| Kenneth Charhut | Director |
| Ken Charhut | Director |
| Jim Demetriades | Director |
| James Demetriades | Director |
| Mory Gharib | Director |
| Morteza Gharib | Director |
| Brant Heise | Director |
| Scott Huennekens | Director |
| Demetriades James | Director |
| Frank Maguire | Director, Executive |
| Renee Masi | Director |
| Scott Richland | Director |
| George Wallace | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
825 N 300 W
Salt Lake City, UT, 84103
Salt Lake City, UT, 84103